Candel Therapeutics (CADL) Other Non-Current Liabilities (2020 - 2023)
Historic Other Non-Current Liabilities for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $433000.0.
- Candel Therapeutics' Other Non-Current Liabilities fell 9063.99% to $433000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $433000.0, marking a year-over-year decrease of 9063.99%. This contributed to the annual value of $1.9 million for FY2022, which is 8968.88% down from last year.
- Latest data reveals that Candel Therapeutics reported Other Non-Current Liabilities of $433000.0 as of Q3 2023, which was down 9063.99% from $1.0 million recorded in Q2 2023.
- In the past 5 years, Candel Therapeutics' Other Non-Current Liabilities ranged from a high of $27.4 million in Q3 2021 and a low of $433000.0 during Q3 2023
- Moreover, its 4-year median value for Other Non-Current Liabilities was $5.0 million (2022), whereas its average is $8.7 million.
- Per our database at Business Quant, Candel Therapeutics' Other Non-Current Liabilities skyrocketed by 16719.37% in 2021 and then plummeted by 9063.99% in 2023.
- Over the past 4 years, Candel Therapeutics' Other Non-Current Liabilities (Quarter) stood at $6.8 million in 2020, then soared by 167.19% to $18.3 million in 2021, then tumbled by 89.69% to $1.9 million in 2022, then plummeted by 76.99% to $433000.0 in 2023.
- Its Other Non-Current Liabilities was $433000.0 in Q3 2023, compared to $1.0 million in Q2 2023 and $1.2 million in Q1 2023.